Rituximab

LCD Information Document Information Source LCD ID N/A LCD ID L35026 Original ICD-9 LCD ID Not Applicable LCD Title Rituximab Proposed LCD in Comment Period N/A Source Proposed LCD N/A Original Effective Date For services performed on or after 10/01/2015 Revision Effective Date For services performed on or after 11/28/2024 Revision Ending Date N/A Retirement Date N/A Notice Period Start Date N/A Notice Period End Date N/A CPT codes, descriptions, and other data only are copyright 2025 American Medical Association. All Rights Reserved. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. CPT is a registered trademark of the American Medical Association. Current Dental Terminology © 2025 American Dental Association. All rights reserved. Copyright © 2026, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB‐04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution, or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at ub04@aha.org or 312‐422‐3366. Making copies or utilizing the content of the UB‐04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB‐04 Manual and/or codes and descriptions; and/or making any commercial use of UB‐04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates. Issue Issue Description This LCD outlines limited coverage for this service with specific details under Coverage Indications, Limitations and/or Medical Necessity. Issue - Explanation of Change Between Proposed LCD and Final LCD CMS National Coverage Policy Title XVIII of the Social Security Act, §1861(t)(2)(B) addresses drugs and biologicals. Title XVIII of the Social Security Act, §1862(a)(1)(A) allows coverage and payment for only those services that are considered to be reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member. Title XVIII of the Social Security Act, §1862(a)(1)(D) addresses investigational or experimental items and services.CMS Internet-Only Manual, Pub. 100-02, Medicare Benefit Policy Manual, Chapter 15, §50 Drugs and Biologicals, §50.1 Definition of Drug or Biological, §50.4.1 Approved Use of Drug, §50.4.2 Unlabeled Use of Drug, §50.4.3 Examples of Not Reasonable and Necessary, §50.4.5 Off-Label Use of Drugs and Biologicals in an Anti-Cancer Chemotherapeutic Regimen Coverage Indications, Limitations, and/or Medical Necessity Rituximab is a genetically engineered chimeric murine/human monoclonal immunoglobulin G1 (IgG1) kappa antibody directed against the CD20 antigen. Rituximab binds specifically to the antigen CD20 (human B-lymphocyte-restricted differentiation antigen, Bp35), a hydrophobic transmembrane protein with a molecular weight of approximately 35 kD located on pre-B and mature B lymphocytes. The antigen is expressed on >90% of B-cell non-Hodgkin’s lymphomas (NHL), but the antigen is not found on hematopoietic stem cells, pro-B-cells, normal plasma cells or other normal tissues. B cells are believed to play a role in the pathogenesis of rheumatoid arthritis (RA) and associated chronic synovitis.In non-Hodgkin’s lymphoma (NHL) patients, administration of rituximab resulted in depletion of circulating and tissue-based B cells.In Wegener's granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) patients, peripheral blood CD19 B-cells depleted to less than 10 cells/µl following the first 2 infusions of rituximab and remained at that level in most (84%) patients through month 6. By month 12, the majority of patients (81%) showed signs of B-cell return with counts >10 cells/µL.Food and Drug Administration (FDA) approved uses:1. NHLRituximab is indicated for the treatment of patients with: Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to Rituximab in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine and prednisone (CVP) chemotherapy. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or other anthracycline-based chemotherapy regimens. 2. Chronic lymphocytic leukemia (CLL)Rituximab is indicated, in combination with fludarabine and cyclophosphamide (FC), for the treatment of patients with previously untreated and previously treated CD20-positive CLL.3. RARituximab in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely active RA who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.4. GPA and MPA Rituximab in combination with glucocorticoids, is indicated for the treatment of adult patients with GPA and MPAAccepted Off-label Uses Approved by this A/B MAC Second-line or salvage therapy with or without radiation therapy (RT) prior to autologous stem cell rescue for progressive disease or for relapsed disease in patients initially treated with chemotherapy with or without RT in combination with bendamustine Low grade or follicular CD20-positive, B-cell NHL (re-induction treatment appropriate for responders and patients with stable disease) Intermediate and high-grade NHL when used as a single agent, in combination with a CHOP chemotherapy regimen, or in combination with other agents active in the disease Immune or idiopathic thrombocytopenia purpura Evans’ syndrome Waldenstrom’s macroglobulinemia For the treatment of refractory thrombotic thrombocytopenic purpura (TTP) for patients who do not respond to plasmapheresis Autoimmune hemolytic anemia - rituximab is covered for those patients with autoimmune hemolytic anemia condition that is refractory to conventional treatment (e.g., corticosteroid treatment and splenectomy) Multifocal motor neuropathy (MMN) as a second line therapy Multiple sclerosis, relapsing, remitting (RRMS) as a third line therapy Neuromyelitis optica Polymyositis as a second or third line therapy Myasthenia gravis Anti-myelin associated glycoprotein (anti-MAG) polyneuropathy Graft-Versus-Host Disease (GVHD) as third line of therapy or greater Antineutrophil cytoplasmic antibody (ANCA) associated vasculitis Rituximab has been shown to be an effective therapy for cryoglobulinemia and cryoglobulinemia induced renal disease with less complications than the standard therapy with cyclophosphamide and plasmapheresis Post-transplant lymphoproliferative disorder (PTLD) Epstein-Barr viremia (EBV) in patients at high risk for PTLD allogenic bone marrow transplant patients with prolonged T-cell immune impairment such as those receiving cord blood units or ex vivo CD34 selected or T-cell-depleted hematopoietic cell grafts, or patients receiving antibodies against T-cells (alemtuzumab), or patients receiving high dose steroids for treatment of severe acute GVHD. Autoimmune encephalitis in bone marrow transplant patients Other off label uses will be considered for coverage at the discretion of this A/B MAC. Summary of Evidence N/A Analysis of Evidence (Rationale for Determination) N/A

Rituximab is a genetically engineered chimeric murine/human monoclonal immunoglobulin G1 (IgG1) kappa antibody directed against the CD20 antigen. Rituximab binds specifically to the antigen CD20 (human B-lymphocyte-restricted differentiation antigen, Bp35), a hydrophobic transmembrane protein with a molecular weight of approximately 35 kD located on pre-B and mature B lymphocytes. The antigen is expressed on >90% of B-cell non-Hodgkin’s lymphomas (NHL), but the antigen is not found on hematopoietic stem cells, pro-B-cells, normal plasma cells or other normal tissues. B cells are believed to play a role in the pathogenesis of rheumatoid arthritis (RA) and associated chronic synovitis. In non-Hodgkin’s lymphoma (NHL) patients, administration of rituximab resulted in depletion of circulating and tissue-based B cells. In Wegener's granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) patients, peripheral blood CD19 B-cells depleted to less than 10 cells/µl following the first 2 infusions of rituximab and remained at that level in most (84%) patients through month 6. By month 12, the majority of patients (81%) showed signs of B-cell return with counts >10 cells/µL. Food and Drug Administration (FDA) approved uses: 1. NHL Rituximab is indicated for the treatment of patients with: Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to Rituximab in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine and prednisone (CVP) chemotherapy. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or other anthracycline-based chemotherapy regimens. 2. Chronic lymphocytic leukemia (CLL) Rituximab is indicated, in combination with fludarabine and cyclophosphamide (FC), for the treatment of patients with previously untreated and previously treated CD20-positive CLL. 3. RA Rituximab in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely active RA who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies. 4. GPA and MPA Rituximab in combination with glucocorticoids, is indicated for the treatment of adult patients with GPA and MPA Accepted Off-label Uses Approved by this A/B MAC Second-line or salvage therapy with or without radiation therapy (RT) prior to autologous stem cell rescue for progressive disease or for relapsed disease in patients initially treated with chemotherapy with or without RT in combination with bendamustine Low grade or follicular CD20-positive, B-cell NHL (re-induction treatment appropriate for responders and patients with stable disease) Intermediate and high-grade NHL when used as a single agent, in combination with a CHOP chemotherapy regimen, or in combination with other agents active in the disease Immune or idiopathic thrombocytopenia purpura Evans’ syndrome Waldenstrom’s macroglobulinemia For the treatment of refractory thrombotic thrombocytopenic purpura (TTP) for patients who do not respond to plasmapheresis Autoimmune hemolytic anemia - rituximab is covered for those patients with autoimmune hemolytic anemia condition that is refractory to conventional treatment (e.g., corticosteroid treatment and splenectomy) Multifocal motor neuropathy (MMN) as a second line therapy Multiple sclerosis, relapsing, remitting (RRMS) as a third line therapy Neuromyelitis optica Polymyositis as a second or third line therapy Myasthenia gravis Anti-myelin associated glycoprotein (anti-MAG) polyneuropathy Graft-Versus-Host Disease (GVHD) as third line of therapy or greater Antineutrophil cytoplasmic antibody (ANCA) associated vasculitis Rituximab has been shown to be an effective therapy for cryoglobulinemia and cryoglobulinemia induced renal disease with less complications than the standard therapy with cyclophosphamide and plasmapheresis Post-transplant lymphoproliferative disorder (PTLD) Epstein-Barr viremia (EBV) in patients at high risk for PTLD allogenic bone marrow transplant patients with prolonged T-cell immune impairment such as those receiving cord blood units or ex vivo CD34 selected or T-cell-depleted hematopoietic cell grafts, or patients receiving antibodies against T-cells (alemtuzumab), or patients receiving high dose steroids for treatment of severe acute GVHD. Autoimmune encephalitis in bone marrow transplant patients Other off label uses will be considered for coverage at the discretion of this A/B MAC.